For years, approved ruxolitinib cream has stopped at age 12. Younger children have had a much shorter menu: steroids, tacrolimus, light therapy if you can get a slot, and a lot of waiting.
Now two Phase III studies are evaluating ruxolitinib cream in younger children. Its use for vitiligo in these age groups is investigational — researchers are still finding out how well it works and how safe it is. Real protocols. Real sites. Not a rumor from a parent group.
Then the catch: they are not the same study. Mix them up and a family books the wrong continent.
In this episode of Deep Dive in Vitiligo, we put the trials side by side.
North American trial TRuE-ViP (NCT06548360) — ages 2 to 11, United States and CanadaThe international trial (NCT06804811, Incyte INCB18424-309) — starts at age 6, Argentina plus 13 European countries, no U.S. or Canadian sitesWhat they share: nonsegmental vitiligo, a 10% body-surface ceiling, active-versus-vehicle treatment during the first 24 weeks, facial scoring at Week 24, and some restrictions.Why an 8-year-old can fit both studies by age and neither by postcode.Do not stop a working routine because two trial pages appeared in the same week. Ask the site what would pause. Then call the child’s regular dermatologist.
Yes is a reasonable answer. No is a reasonable answer. The useful question is which protocol — if either — fits this child, in this country, with this schedule.
Both studies discussed in this episode are sponsored by Incyte Corporation. VRF provides patient education and study-awareness support related to Incyte pediatric vitiligo research under a paid services agreement. VRF does not determine study eligibility or recommend participation.
📚 Prefer reading to listening? These two companion articles expand on many of the themes discussed in this episode.
Vitiligo Study For Children Ages 2–11 in USA and Canada Vitiligo Study For Children Ages 6-11, International